Cellectis : Une modification de son accord avec Servier
>Avenant à son accord de licence avec Servier - Cellectis vient d’annoncer avoir procédé à un avenant sur son accord initial avec Servier. Celui-ci permettra à Servier d’obtenir une licence mondiale exclusive pour le développement suivi de la commercialisation de l’ensemble des produits ciblant CD19 (y compris ALLO-501A). En parallèle, Cellectis reprendra la main sur ses cinq développements donnés initialement sous licence à Servier mais dont les cibles n’avaient jama...Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.